Evidence map›Paper›PMID 34578339›Full record

ArticleViruses2021

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.

XuSha Zhou, Jing Zhao, Jian V Zhang, Yinglin Wu, Lei Wang, Xiaoqing Chen, Dongmei Ji, Grace Guoying Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors.Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

XuSha ZhouShenzhen International Institute for Biomedical Research, Shenzhen 518110, China.
Jing ZhaoShenzhen International Institute for Biomedical Research, Shenzhen 518110, China.
Jian V ZhangCenter for Energy Metabolism and Reproduction, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Yinglin WuDepartment of Immunology, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Lei WangDepartment of Immunology, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Xiaoqing ChenShenzhen International Institute for Biomedical Research, Shenzhen 518110, China.
Dongmei JiDepartment of Medical Oncology, Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai 200032, China.
Grace Guoying ZhouShenzhen International Institute for Biomedical Research, Shenzhen 518110, China.
Shenzhen Institute of Information Technology · CNGuangzhou Medical University · CNFudan University Shanghai Cancer Center · CNShenzhen Institutes of Advanced Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic virus (OV) as a promising therapeutic agent can selectively infect and kill tumor cells with naturally inherited or engineered properties. Considering the limitations of OVs monotherapy, combination therapy has been widely explored. MEK inhibitor (MEKi) Trametinib is an FDA-approved kinase inhibitor indicated for the treatment of tumors with BRAF V600E or V600K mutations. In this study, the oncolytic activity in vitro and anti-tumor therapeutic efficacy in vivo when combined with oHSV and MEKi Trametinib were investigated. We found: (1) Treatment with MEKi Trametinib augmented oHSV oncolytic activity in BRAF V600E-mutated tumor cells. (2) Combination treatment with oHSV and MEKi Trametinib enhanced virus replication mediated by down-regulation of STAT1 and PKR expression or phosphorylation in BRAF V600E-mutated tumor cells as well as BRAF wt/KRAS-mutated tumor cells. (3) A remarkably synergistic therapeutic efficacy was shown in vivo for BRAF wt/KRAS-mutated tumor models, when a combination of oHSV including PD-1 blockade and MEK inhibition. Collectively, these data provide some new insights for clinical development of combination therapy with oncolytic virus, MEK inhibition, and checkpoint blockade for BRAF or KRAS-mutated tumors.

Indexed as

AnimalsAntineoplastic AgentsCarcinomaCell Line, TumorChlorocebus aethiopsColorectal NeoplasmsFemaleHumansLungLung NeoplasmsMiceMice, Inbred BALB CMice, Inbred C57BLMitogen-Activated Protein Kinase KinasesOncolytic VirotherapyOncolytic VirusesAntineoplastic AgentsBRAF protein, humanKRAS protein, humanMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)PyridonesPyrimidinonesSTAT1 Transcription FactortrametinibantitumorBRAFKRASMEKi trametiniboHSV

Identifiers

PMID34578339
PMCPMC8473197
OpenAlexW3197008107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.